Efficacy of pioglitazone in familial partial lipodystrophy of the Dunnigan type: a case report

• Published in: Diabetes & metabolism Vol. 33; no. 5; pp. 385 - 389
• Main Authors: Moreau, F, Boullu-Sanchis, S, Vigouroux, C, Lucescu, C, Lascols, O, Sapin, R, Ruimy, D, Guerci, B, Pinget, M, Jeandidier, N
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.11.2007
• Subjects: Adipose Tissue - anatomy & histology; Adipose Tissue - pathology; Adult; Body Mass Index; Body Size; Dunnigan lipodystrophy; Endocrinology & Metabolism; Female; Humans; Hypertriglyceridemia; Hypertriglycéridémie; Hypoglycemic Agents - therapeutic use; Insulin resistance; Insulinorésistance; Internal Medicine; Lipodystrophie de Dunnigan; Lipodystrophy, Familial Partial - drug therapy; Lipodystrophy, Familial Partial - pathology; Pioglitazone; Thiazolidinediones - therapeutic use; Dunnigan lipodystrophy; Oral glucose tolerance test; Lipodystrophie de Dunnigan; PPARy; Dunnigan-type-familial partial lipodystrophy; Pioglitazone; Hypertriglycéridémie; FPLD2; Insulinorésistance; Body mass index; Peroxisome proliferator activated receptor y; Hypertriglyceridemia; Insulin resistance; OGTT; BMI
• ISSN: 1262-3636; 1878-1780
• DOI: 10.1016/j.diabet.2007.04.005

Abstract A 25 year old woman consulted for a severe acanthosis nigricans and central distribution of fat. Her masculine type morphology was associated with muscular appearance of the limbs and excess fat deposits in the face and neck. Biological testing confirmed glucose intolerance associated with a severe insulin resistance, hypertriglyceridemia and polycystic ovary syndrome. The detection of a heterozygous missense mutation in LAMIN A/C gene at position 482 confirmed the diagnosis of Familial Partial Lipodystrophy (FPLD2). Due to a deterioration of clinical and metabolic status, 15 and then 30 mg per day of pioglitazone were added to her previous treatment with metformin, bezafibrate and omega-3 fatty acids. Metabolic status improved rapidly after 3 months and continued thereafter. Weight remained stable, body mass composition and waist circumference improved. After 18 months of treatment, glycaemia and triglycerides levels normalized, hepatic enzymes and liver echographic features improved. Insulin sensitivity improved dramatically with a HOMA % S value of 73% with metformin and of 98.2% when pioglitazone was added. Leptin levels increased from 6.6 to 10.2 μg/ml. We report a very rapid and good efficacy of pioglitazone added to metformin without side effects in FPLD2. If confirmed on more patients, early use of pioglitazone in association with metformin could be proposed in FPLD2.